PMC:7546716 / 33739-34331 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T617","span":{"begin":21,"end":25},"obj":"Body_part"},{"id":"T618","span":{"begin":60,"end":62},"obj":"Body_part"},{"id":"T619","span":{"begin":83,"end":86},"obj":"Body_part"},{"id":"T620","span":{"begin":103,"end":108},"obj":"Body_part"},{"id":"T621","span":{"begin":126,"end":135},"obj":"Body_part"},{"id":"T622","span":{"begin":136,"end":147},"obj":"Body_part"},{"id":"T623","span":{"begin":178,"end":189},"obj":"Body_part"},{"id":"T624","span":{"begin":195,"end":205},"obj":"Body_part"},{"id":"T625","span":{"begin":200,"end":205},"obj":"Body_part"},{"id":"T626","span":{"begin":284,"end":289},"obj":"Body_part"},{"id":"T627","span":{"begin":317,"end":319},"obj":"Body_part"},{"id":"T628","span":{"begin":343,"end":347},"obj":"Body_part"},{"id":"T629","span":{"begin":379,"end":381},"obj":"Body_part"},{"id":"T630","span":{"begin":387,"end":389},"obj":"Body_part"},{"id":"T631","span":{"begin":399,"end":401},"obj":"Body_part"},{"id":"T632","span":{"begin":439,"end":447},"obj":"Body_part"},{"id":"T633","span":{"begin":549,"end":559},"obj":"Body_part"},{"id":"T634","span":{"begin":554,"end":559},"obj":"Body_part"}],"attributes":[{"id":"A617","pred":"fma_id","subj":"T617","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A618","pred":"fma_id","subj":"T618","obj":"http://purl.org/sig/ont/fma/fma86578"},{"id":"A619","pred":"fma_id","subj":"T619","obj":"http://purl.org/sig/ont/fma/fma20935"},{"id":"A620","pred":"fma_id","subj":"T620","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A621","pred":"fma_id","subj":"T621","obj":"http://purl.org/sig/ont/fma/fma62864"},{"id":"A622","pred":"fma_id","subj":"T622","obj":"http://purl.org/sig/ont/fma/fma63261"},{"id":"A623","pred":"fma_id","subj":"T623","obj":"http://purl.org/sig/ont/fma/fma62860"},{"id":"A624","pred":"fma_id","subj":"T624","obj":"http://purl.org/sig/ont/fma/fma66784"},{"id":"A625","pred":"fma_id","subj":"T625","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A626","pred":"fma_id","subj":"T626","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A627","pred":"fma_id","subj":"T627","obj":"http://purl.org/sig/ont/fma/fma86578"},{"id":"A628","pred":"fma_id","subj":"T628","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A629","pred":"fma_id","subj":"T629","obj":"http://purl.org/sig/ont/fma/fma86578"},{"id":"A630","pred":"fma_id","subj":"T630","obj":"http://purl.org/sig/ont/fma/fma86578"},{"id":"A631","pred":"fma_id","subj":"T631","obj":"http://purl.org/sig/ont/fma/fma86578"},{"id":"A632","pred":"fma_id","subj":"T632","obj":"http://purl.org/sig/ont/fma/fma84050"},{"id":"A633","pred":"fma_id","subj":"T633","obj":"http://purl.org/sig/ont/fma/fma66784"},{"id":"A634","pred":"fma_id","subj":"T634","obj":"http://purl.org/sig/ont/fma/fma68646"}],"text":"Additional important cell targets to focus on include ILC2, IL-17-producing and GM-CSF-producing γδT17 cells, proinflammatory monocytes–macrophages, extracellular trap-producing neutrophils, and mast cells. Different strategies could be set up to control aberrant activation of these cells, for instance by targeting IL-9 (MEDI-528), Vγ9Vδ2 T-cell activation (pentoxifylline),74 IL-17A, IL-17F, and IL-17E (bimekizumab, brodalumab),92 and cytokine balance (using colchicine,93 NLRP3 inhibitors,94 TLR2 inhibitors,95 JAK2 inhibitors,96 apremilast,97 mast cells stabilisers,55 and vitamin D).98"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T458","span":{"begin":21,"end":25},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T459","span":{"begin":37,"end":42},"obj":"http://purl.obolibrary.org/obo/CLO_0009985"},{"id":"T460","span":{"begin":99,"end":102},"obj":"http://purl.obolibrary.org/obo/CLO_0050389"},{"id":"T461","span":{"begin":103,"end":108},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T462","span":{"begin":126,"end":135},"obj":"http://purl.obolibrary.org/obo/CL_0000576"},{"id":"T463","span":{"begin":200,"end":205},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T464","span":{"begin":264,"end":274},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T465","span":{"begin":284,"end":289},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T466","span":{"begin":328,"end":331},"obj":"http://purl.obolibrary.org/obo/CLO_0001409"},{"id":"T467","span":{"begin":341,"end":347},"obj":"http://purl.obolibrary.org/obo/CL_0000084"},{"id":"T468","span":{"begin":348,"end":358},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T469","span":{"begin":494,"end":496},"obj":"http://purl.obolibrary.org/obo/CLO_0001527"},{"id":"T470","span":{"begin":497,"end":501},"obj":"http://purl.obolibrary.org/obo/CLO_0050768"},{"id":"T471","span":{"begin":554,"end":559},"obj":"http://purl.obolibrary.org/obo/GO_0005623"}],"text":"Additional important cell targets to focus on include ILC2, IL-17-producing and GM-CSF-producing γδT17 cells, proinflammatory monocytes–macrophages, extracellular trap-producing neutrophils, and mast cells. Different strategies could be set up to control aberrant activation of these cells, for instance by targeting IL-9 (MEDI-528), Vγ9Vδ2 T-cell activation (pentoxifylline),74 IL-17A, IL-17F, and IL-17E (bimekizumab, brodalumab),92 and cytokine balance (using colchicine,93 NLRP3 inhibitors,94 TLR2 inhibitors,95 JAK2 inhibitors,96 apremilast,97 mast cells stabilisers,55 and vitamin D).98"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T488","span":{"begin":60,"end":62},"obj":"Chemical"},{"id":"T490","span":{"begin":80,"end":82},"obj":"Chemical"},{"id":"T491","span":{"begin":317,"end":319},"obj":"Chemical"},{"id":"T493","span":{"begin":379,"end":381},"obj":"Chemical"},{"id":"T495","span":{"begin":387,"end":389},"obj":"Chemical"},{"id":"T497","span":{"begin":399,"end":401},"obj":"Chemical"},{"id":"T499","span":{"begin":463,"end":473},"obj":"Chemical"},{"id":"T500","span":{"begin":483,"end":493},"obj":"Chemical"},{"id":"T501","span":{"begin":502,"end":512},"obj":"Chemical"},{"id":"T502","span":{"begin":516,"end":531},"obj":"Chemical"},{"id":"T503","span":{"begin":521,"end":531},"obj":"Chemical"},{"id":"T504","span":{"begin":535,"end":545},"obj":"Chemical"},{"id":"T505","span":{"begin":560,"end":571},"obj":"Chemical"},{"id":"T506","span":{"begin":579,"end":588},"obj":"Chemical"},{"id":"T507","span":{"begin":579,"end":586},"obj":"Chemical"}],"attributes":[{"id":"A488","pred":"chebi_id","subj":"T488","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A489","pred":"chebi_id","subj":"T488","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A490","pred":"chebi_id","subj":"T490","obj":"http://purl.obolibrary.org/obo/CHEBI_74120"},{"id":"A491","pred":"chebi_id","subj":"T491","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A492","pred":"chebi_id","subj":"T491","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A493","pred":"chebi_id","subj":"T493","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A494","pred":"chebi_id","subj":"T493","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A495","pred":"chebi_id","subj":"T495","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A496","pred":"chebi_id","subj":"T495","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A497","pred":"chebi_id","subj":"T497","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A498","pred":"chebi_id","subj":"T497","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A499","pred":"chebi_id","subj":"T499","obj":"http://purl.obolibrary.org/obo/CHEBI_23359"},{"id":"A500","pred":"chebi_id","subj":"T500","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A501","pred":"chebi_id","subj":"T501","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A502","pred":"chebi_id","subj":"T502","obj":"http://purl.obolibrary.org/obo/CHEBI_76617"},{"id":"A503","pred":"chebi_id","subj":"T503","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A504","pred":"chebi_id","subj":"T504","obj":"http://purl.obolibrary.org/obo/CHEBI_78540"},{"id":"A505","pred":"chebi_id","subj":"T505","obj":"http://purl.obolibrary.org/obo/CHEBI_77966"},{"id":"A506","pred":"chebi_id","subj":"T506","obj":"http://purl.obolibrary.org/obo/CHEBI_27300"},{"id":"A507","pred":"chebi_id","subj":"T507","obj":"http://purl.obolibrary.org/obo/CHEBI_33229"}],"text":"Additional important cell targets to focus on include ILC2, IL-17-producing and GM-CSF-producing γδT17 cells, proinflammatory monocytes–macrophages, extracellular trap-producing neutrophils, and mast cells. Different strategies could be set up to control aberrant activation of these cells, for instance by targeting IL-9 (MEDI-528), Vγ9Vδ2 T-cell activation (pentoxifylline),74 IL-17A, IL-17F, and IL-17E (bimekizumab, brodalumab),92 and cytokine balance (using colchicine,93 NLRP3 inhibitors,94 TLR2 inhibitors,95 JAK2 inhibitors,96 apremilast,97 mast cells stabilisers,55 and vitamin D).98"}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T91","span":{"begin":341,"end":358},"obj":"http://purl.obolibrary.org/obo/GO_0042110"},{"id":"T92","span":{"begin":343,"end":358},"obj":"http://purl.obolibrary.org/obo/GO_0001775"}],"text":"Additional important cell targets to focus on include ILC2, IL-17-producing and GM-CSF-producing γδT17 cells, proinflammatory monocytes–macrophages, extracellular trap-producing neutrophils, and mast cells. Different strategies could be set up to control aberrant activation of these cells, for instance by targeting IL-9 (MEDI-528), Vγ9Vδ2 T-cell activation (pentoxifylline),74 IL-17A, IL-17F, and IL-17E (bimekizumab, brodalumab),92 and cytokine balance (using colchicine,93 NLRP3 inhibitors,94 TLR2 inhibitors,95 JAK2 inhibitors,96 apremilast,97 mast cells stabilisers,55 and vitamin D).98"}

{"project":"LitCovid-sentences","denotations":[{"id":"T138","span":{"begin":0,"end":206},"obj":"Sentence"},{"id":"T139","span":{"begin":207,"end":592},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Additional important cell targets to focus on include ILC2, IL-17-producing and GM-CSF-producing γδT17 cells, proinflammatory monocytes–macrophages, extracellular trap-producing neutrophils, and mast cells. Different strategies could be set up to control aberrant activation of these cells, for instance by targeting IL-9 (MEDI-528), Vγ9Vδ2 T-cell activation (pentoxifylline),74 IL-17A, IL-17F, and IL-17E (bimekizumab, brodalumab),92 and cytokine balance (using colchicine,93 NLRP3 inhibitors,94 TLR2 inhibitors,95 JAK2 inhibitors,96 apremilast,97 mast cells stabilisers,55 and vitamin D).98"}

{"project":"LitCovid-PubTator","denotations":[{"id":"1431","span":{"begin":60,"end":65},"obj":"Gene"},{"id":"1432","span":{"begin":80,"end":86},"obj":"Gene"},{"id":"1433","span":{"begin":317,"end":321},"obj":"Gene"},{"id":"1434","span":{"begin":379,"end":385},"obj":"Gene"},{"id":"1435","span":{"begin":387,"end":393},"obj":"Gene"},{"id":"1436","span":{"begin":399,"end":405},"obj":"Gene"},{"id":"1437","span":{"begin":477,"end":482},"obj":"Gene"},{"id":"1438","span":{"begin":497,"end":501},"obj":"Gene"},{"id":"1439","span":{"begin":516,"end":520},"obj":"Gene"},{"id":"1440","span":{"begin":360,"end":374},"obj":"Chemical"},{"id":"1441","span":{"begin":407,"end":418},"obj":"Chemical"},{"id":"1442","span":{"begin":420,"end":430},"obj":"Chemical"},{"id":"1443","span":{"begin":463,"end":473},"obj":"Chemical"},{"id":"1444","span":{"begin":579,"end":588},"obj":"Chemical"},{"id":"1445","span":{"begin":334,"end":342},"obj":"CellLine"}],"attributes":[{"id":"A1431","pred":"tao:has_database_id","subj":"1431","obj":"Gene:3605"},{"id":"A1432","pred":"tao:has_database_id","subj":"1432","obj":"Gene:1437"},{"id":"A1433","pred":"tao:has_database_id","subj":"1433","obj":"Gene:3578"},{"id":"A1434","pred":"tao:has_database_id","subj":"1434","obj":"Gene:3605"},{"id":"A1435","pred":"tao:has_database_id","subj":"1435","obj":"Gene:112744"},{"id":"A1436","pred":"tao:has_database_id","subj":"1436","obj":"Gene:64806"},{"id":"A1437","pred":"tao:has_database_id","subj":"1437","obj":"Gene:114548"},{"id":"A1438","pred":"tao:has_database_id","subj":"1438","obj":"Gene:7097"},{"id":"A1439","pred":"tao:has_database_id","subj":"1439","obj":"Gene:3717"},{"id":"A1440","pred":"tao:has_database_id","subj":"1440","obj":"MESH:D010431"},{"id":"A1441","pred":"tao:has_database_id","subj":"1441","obj":"MESH:C000625981"},{"id":"A1442","pred":"tao:has_database_id","subj":"1442","obj":"MESH:C571216"},{"id":"A1443","pred":"tao:has_database_id","subj":"1443","obj":"MESH:D003078"},{"id":"A1444","pred":"tao:has_database_id","subj":"1444","obj":"MESH:D014807"},{"id":"A1445","pred":"tao:has_database_id","subj":"1445","obj":"CVCL:M092"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Additional important cell targets to focus on include ILC2, IL-17-producing and GM-CSF-producing γδT17 cells, proinflammatory monocytes–macrophages, extracellular trap-producing neutrophils, and mast cells. Different strategies could be set up to control aberrant activation of these cells, for instance by targeting IL-9 (MEDI-528), Vγ9Vδ2 T-cell activation (pentoxifylline),74 IL-17A, IL-17F, and IL-17E (bimekizumab, brodalumab),92 and cytokine balance (using colchicine,93 NLRP3 inhibitors,94 TLR2 inhibitors,95 JAK2 inhibitors,96 apremilast,97 mast cells stabilisers,55 and vitamin D).98"}

{"project":"2_test","denotations":[{"id":"33073244-17880773-66244652","span":{"begin":376,"end":378},"obj":"17880773"},{"id":"33073244-32358580-66244653","span":{"begin":432,"end":434},"obj":"32358580"},{"id":"33073244-27521339-66244654","span":{"begin":494,"end":496},"obj":"27521339"},{"id":"33073244-20603154-66244655","span":{"begin":513,"end":515},"obj":"20603154"},{"id":"33073244-32205092-66244656","span":{"begin":532,"end":534},"obj":"32205092"},{"id":"33073244-20050849-66244657","span":{"begin":546,"end":548},"obj":"20050849"}],"text":"Additional important cell targets to focus on include ILC2, IL-17-producing and GM-CSF-producing γδT17 cells, proinflammatory monocytes–macrophages, extracellular trap-producing neutrophils, and mast cells. Different strategies could be set up to control aberrant activation of these cells, for instance by targeting IL-9 (MEDI-528), Vγ9Vδ2 T-cell activation (pentoxifylline),74 IL-17A, IL-17F, and IL-17E (bimekizumab, brodalumab),92 and cytokine balance (using colchicine,93 NLRP3 inhibitors,94 TLR2 inhibitors,95 JAK2 inhibitors,96 apremilast,97 mast cells stabilisers,55 and vitamin D).98"}